lubiprostone has been researched along with Disease Models, Animal in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akita, H; Hazama, A; Ishida, T; Takeishi, Y; Yoshie, S | 1 |
| Arakawa, K; Chen, L; Doi, H; Hibi, K; Ishigami, T; Kimura, K; Kino, T; Minegishi, S; Nakai-Sugiyama, M; Saigoh-Teranaka, S; Sasaki-Nakashima, R; Tamura, K | 1 |
| Morgan, B | 1 |
| Blikslager, AT; Moeser, AJ; Nighot, PK; Roerig, B; Ueno, R | 1 |
| De Lisle, RC; Mueller, R; Roach, E | 1 |
5 other study(ies) available for lubiprostone and Disease Models, Animal
| Article | Year |
|---|---|
Negative chronotropic and inotropic effects of lubiprostone on iPS cell-derived cardiomyocytes via activation of CFTR.
Topics: Animals; Cells, Cultured; Chloride Channel Agonists; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Animal; Induced Pluripotent Stem Cells; Lubiprostone; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myocytes, Cardiac | 2020 |
Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Chloride Channel Agonists; Chloride Channels; CLC-2 Chloride Channels; Cytokines; Diet, Western; Disease Models, Animal; Ileum; Immunoglobulins; Inflammation; Intestinal Mucosa; Lubiprostone; Mice; Mice, Inbred C57BL; Occludin; Permeability; Tight Junction Proteins; Zonula Occludens-1 Protein | 2019 |
Drug development: A healthy pipeline.
Topics: Animals; Benzimidazoles; Benzofurans; Bile Acids and Salts; Carbolines; Colesevelam Hydrochloride; Colestipol; Disease Models, Animal; Enteric Nervous System; Female; Humans; Imidazoles; Indoles; Irritable Bowel Syndrome; Loperamide; Lubiprostone; Male; Mice; Natriuretic Peptides; Peptides; Phenylalanine; Receptors, Serotonin, 5-HT3; Receptors, Serotonin, 5-HT4; Rifamycins; Rifaximin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Visceral Pain | 2016 |
Comparison of the chloride channel activator lubiprostone and the oral laxative Polyethylene Glycol 3350 on mucosal barrier repair in ischemic-injured porcine intestine.
Topics: Alprostadil; Animals; Cell Membrane Permeability; Chloride Channel Agonists; Disease Models, Animal; Epithelial Cells; Female; Ileum; Intestinal Mucosa; Inulin; Laxatives; Lubiprostone; Male; Mannitol; Polyethylene Glycols; Recovery of Function; Reperfusion Injury; Swine | 2008 |
Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.
Topics: Alprostadil; Animals; Bacteria; Bacterial Load; Chloride Channels; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Animal; Immunity, Innate; Intestine, Small; Lubiprostone; Mice; Mice, Inbred C57BL; Phenotype | 2010 |